Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.

Overview
Date Founded

2006

Headquarters

1035 O'BRIEN DRIVE SUITE A MENLO PARK CA 94025

Type of Company

Public

Employees (Worldwide)

82

Industries

Biotechnology
Pharmaceuticals

Company Description

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Adverum Biotechnologies, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director & Chief Executive Officer

Executive Director, Process Development & Manufacturing

Executive Director, Pharmaceutical Development

Chief Financial Officer

Chief Medical Officer

Chief Legal Officer

Vice President, Human Resources

Vice President, Quality

Vice President, Program Management & Strategy

Vice President, Investor Relations & Corporate Communications

Board of Directors

Co-Founder at Medivation, Inc.

Venture Partner at Versant Venture Management LLC

Managing Director at Mpm Capital LLC

Director & Chief Executive Officer at Adverum Biotechnologies, Inc.

Former Chief Operating Officer at Rapt Therapeutics, Inc.

Former Associate Professor at The University of North Carolina at Chapel Hill

Former President & Chief Scientific Officer at Adverum Biotechnologies, Inc.

Member-Councilors Board at University of Southern California

Vice President-Translational Pharmacology & Preclinical Development at Sutro Biopharma, Inc.

Paths to Adverum Biotechnologies, Inc.
Potential Connections via
Relationship Science
You
Adverum Biotechnologies, Inc.
Owners & Shareholders
Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Details Hidden

venBio Select Advisors' investment objective is to achieve attractive returns with moderate risk. The firm invests primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries.

Details Hidden

Ghost Tree Capital seeks to generate absolute returns in the funds that aim to be uncorrelated to broader market conditions by utilizing a long/short equity strategy principally focused on the healthcare industry. By leveraging the medical and financial experience of the Principal and other investment personnel, the firm expects to pursue investments primarily in the areas of biotechnology, pharmaceuticals, medical devices and supplies and healthcare services. However, they generally have broad and flexible investment authority with respect to the funds. Ghost Tree Capital's research process is focus on forming differentiated views and unique insights into critical value drivers that impact individual company, competitive markets, therapeutic categories and the broader healthcare industry, in order to attempt to identify compelling investments for the funds.

Recent Transactions
Details Hidden

Adverum Biotechnologies, Inc. issued . USD Common Stock

Details Hidden

Adverum Biotechnologies, Inc. purchases Annapurna Therapeutics SAS

Details Hidden

Adverum Biotechnologies, Inc. issued Common Stock

Transaction Advisors
Underwriter

Advised onAdverum Biotechnologies, Inc. issued Common Stock

Auditor

Advised onAdverum Biotechnologies, Inc. issued Common Stock

Legal Advisor

Advised onAdverum Biotechnologies, Inc. issued Common Stock

Associate

Advised onAdverum Biotechnologies, Inc. purchases Annapurna Therapeutics SAS

Managing Director

Advised onAdverum Biotechnologies, Inc. issued . USD Common Stock

Managing Director, ECM

Advised onAdverum Biotechnologies, Inc. issued . USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Cooley LLP

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Consultant

Chief Operating Officer at Oncorus, Inc.

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2018
Market Capitalization
$514M
Total Enterprise Value
$-11.7M
Earnings Per Share
$-1.18
Net Profit
$-72.6M
EBITDA
$-71.3M
EBITDAMargin
-4,425%
Total Debt
$0
Total Equity
$201M
Enterprise Value Sales
-7.29x
TEVNet Income
0.16x
Debt TEV
0x
Revenue
$1.61M
Five Year Compounded Annual Growth Rate Of Revenue
27.42%
Three Year Compounded Annual Growth Rate Of Revenue
-11.42%
Investors
Details Hidden

Deerfield Management Co. LP (Private Equity) invests in a broad range of industries. It provides financing for buyout transactions to private and public companies located in the U.S.

Details Hidden

Chief Business Officer at Pliant Therapeutics, Inc.

Details Hidden
Suppliers
University of California Investment Services & Portfolio Management

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Virovek, Inc. Biotechnology | Hayward, CA

Virovek, Inc. is an American private company located in Hayward, CA, that operates as an adeno-associated virus production and protein expression services company.

Government of France Government | Paris, IF

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adverum Biotechnologies, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adverum Biotechnologies, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Adverum Biotechnologies, Inc..